State Street
AEON icon

State Street’s AEON Biopharma AEON Stock Holding History

State Street’s Portfolio AEON Stock Details AEON Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-847
Closed -$32.9K – 4282
2024
Q4 		$32.9K Hold
847
– – ﹤0.01% 4176
2024
Q3 		$64K Hold
847
– – ﹤0.01% 4057
2024
Q2 		$64K Buy
847
+20
+2% +$4.77K ﹤0.01% 4101
2024
Q1 		$691K Buy
827
+687
+491% +$498K ﹤0.01% 3564
2023
Q4 		$72.4K Buy
+140
New +$56.2K ﹤0.01% 4124

Other funds holding AEON

DIG
Dauntless Investment Group Etna, New Hampshire $151M AUM 76.14% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
DCM
Dupont Capital Management Wilmington, Delaware $2.18M AUM 50.81% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.25% 1-Year Est. Return
SPIA
Steward Partners Investment Advisory New York $19.6B AUM 22.89% 1-Year Est. Return

State Street's AEON Position: Q1 2025 in Review

State Street sold out of AEON Biopharma (AEON) in Q1 2025, closing a stake of 847 shares — an estimated $32.9K sold.

State Street first reported a position in AEON in Q4 2023 and held it in 5 quarters. The position peaked at $691K in Q1 2024. 16 funds tracked by Wall St. Rank hold AEON as of Q1 2025.

  • State Street reported no remaining AEON Biopharma position as of Q1 2025 after selling out during the quarter.
  • State Street sold 847 AEON Biopharma shares in Q1 2025, an estimated $32.9K.
  • State Street first reported a position in AEON Biopharma in Q4 2023 and held it in 5 quarters.
  • State Street's AEON Biopharma position peaked at $691K in Q1 2024.
  • 16 funds tracked by Wall St. Rank held AEON Biopharma as of Q1 2025.

Based on State Street's 13F filing for Q1 2025, filed 15 May 2025.